These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
171 related articles for article (PubMed ID: 349501)
1. [Effect on serum aluminium levels of continued ingestion of aluminium gels by patients with chronic renal insufficiency (author's transl)]. Boukari M; Rottembourg J; Jaudon MC; Clavel JP; Legrain M; Galli A Nouv Presse Med; 1978 Jan; 7(2):85-8. PubMed ID: 349501 [TBL] [Abstract][Full Text] [Related]
2. Aluminum, zinc and copper concentrations in plasma in chronic renal insufficiency. Zumkley H; Bertram HP; Lison A; Knoll O; Losse H Clin Nephrol; 1979 Jul; 12(1):18-21. PubMed ID: 477052 [TBL] [Abstract][Full Text] [Related]
3. [Kinetics of aluminum absorption and serum concentration in chronic renal insufficiency]. Sárszegi Z; Jobst K; Nagy J Orv Hetil; 2000 Aug; 141(35):1915-7. PubMed ID: 11019592 [TBL] [Abstract][Full Text] [Related]
4. [Prolonged and reversible encephalopathy in a chronic haemodialysis patient. Probable responsibility of aluminium salts (author's transl)]. Buge A; Poisson M; Masson S; Bleibel JM; Lafforgue B; Raymond P; Jaudon MC Nouv Presse Med; 1978 Jun; 7(23):2053-9. PubMed ID: 673773 [TBL] [Abstract][Full Text] [Related]
5. [Determination of the plasma aluminum concentration of hemodialysis patients]. Kuleva V; Petrov I; Antonov S; Kiriakov Z Vutr Boles; 1984; 23(2):51-5. PubMed ID: 6741112 [TBL] [Abstract][Full Text] [Related]
6. [Aluminum-balance during haemodialysis (author's transl)]. Graf H; Stummvoll HK; Kovarik J; Meisinger V; Wolf A; Pinggera WF Wien Klin Wochenschr; 1980; 92(11):391-4. PubMed ID: 7424016 [TBL] [Abstract][Full Text] [Related]
7. Level-dependent inhibitory effect of hyperaluminaemia on parathyroid hormone secretion in patients with end-stage renal failure. Fernández E; Amoedo ML; Montoliu J Eur J Med; 1992 Dec; 1(8):482-4. PubMed ID: 1341207 [TBL] [Abstract][Full Text] [Related]
8. Aluminum hydroxide, calcium carbonate and calcium acetate in chronic intermittent hemodialysis patients. Janssen MJ; van der Kuy A; ter Wee PM; van Boven WP Clin Nephrol; 1996 Feb; 45(2):111-9. PubMed ID: 8846523 [TBL] [Abstract][Full Text] [Related]
9. Low serum aluminum values in dialysis patients with increased bone aluminum levels. van Landeghem GF; D'Haese PC; Lamberts LV; Djukanovic L; Pejanovic S; Goodman WG; De Broe ME Clin Nephrol; 1998 Aug; 50(2):69-76. PubMed ID: 9725776 [TBL] [Abstract][Full Text] [Related]
10. [Reversible dialytic encephalopathy after interruption of aluminium intake. 6 cases (author's transl)]. Buge A; Poisson M; Masson S; Bleibel JM; Mashaly R; Jaudon MC; Lafforgue B; Lebkiri B; Raymond P Nouv Presse Med; 1979 Sep; 8(34):2729-33. PubMed ID: 493078 [TBL] [Abstract][Full Text] [Related]
11. [Progressive dialytic encephalopathy. Role of the aluminium and neurological study. One case (author's transl)]. Buge A; Escourolle R; Poisson M; Gray F; Bleibel JM; Jaudon MC Nouv Presse Med; 1979 Mar; 8(13):1071-4. PubMed ID: 461135 [TBL] [Abstract][Full Text] [Related]
12. [Aluminum absorption in the presence of normal kidney function: the effect of the pH]. Olaizola Ottonello I; Serrano Arias M; Vizoso Piñeiro F; Rodrigo Saez L; García Morán M; Cannata Andía JB Rev Clin Esp; 1991 May; 188(9):442-5. PubMed ID: 1896590 [TBL] [Abstract][Full Text] [Related]
13. Serum aluminium measurement by DC plasma emission spectrometry. Roberts NB; Williams P Ann Clin Biochem; 1988 Mar; 25 ( Pt 2)():169-75. PubMed ID: 3382147 [TBL] [Abstract][Full Text] [Related]
14. [The natural history of dialysis encephalopathy (author's transl)]. Pogglitsch H; Wawschinek O; Holzer H; Petek W; Ladurner G; Katschnig H; Korthals C Acta Med Austriaca; 1980; 7(3):71-6. PubMed ID: 7223340 [TBL] [Abstract][Full Text] [Related]
15. [Aluminum poisoning caused by the phosphate binder in a non-dialysed child with chronic renal insufficiency]. Feldmann B; Färber D; Pontz BF Radiologe; 1992 Jul; 32(7):327-32. PubMed ID: 1509030 [TBL] [Abstract][Full Text] [Related]
16. Plasma aluminium levels in patients on maintenance haemodialysis fall when oral aluminium hydroxide is withdrawn. Wallace MR; Pybus J N Z Med J; 1983 Oct; 96(742):793-5. PubMed ID: 6578451 [TBL] [Abstract][Full Text] [Related]
17. Aluminium encephalopathy: a potential risk of aluminium gels in children with chronic renal failure. Pillion G; Loirat C; Blum C; Poisson M; Bacri JL; Broyer M; Mathieu H Int J Pediatr Nephrol; 1981 Mar; 2(1):29-32. PubMed ID: 7333766 [No Abstract] [Full Text] [Related]
18. Aluminium load in patients with analgesic nephropathy. Schwarz A; Kraft D; Keller F; Gawlik D; Offermann G Miner Electrolyte Metab; 1987; 13(3):141-6. PubMed ID: 3627045 [TBL] [Abstract][Full Text] [Related]
19. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis. Brandi L Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159 [TBL] [Abstract][Full Text] [Related]
20. In end-stage renal failure, does infection lead to elevated plasma aluminium and neurotoxicity? Implications for monitoring. Fenwick S; Roberts EA; Mahesh BS; Roberts NB Ann Clin Biochem; 2005 Mar; 42(Pt 2):149-52. PubMed ID: 15829127 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]